Jules Bordet Institute
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 1939-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.bordet.be
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 90
- Registration Number
- NCT01565200
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇳🇱Vrije Universiteit Amsterdam (VUMC), Amsterdam, Netherlands
🇧🇪Universitair Ziekenhuis Antwerpen (UZA), Antwerpen, Edegem, Belgium
Late Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer Patients
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 73
- Registration Number
- NCT01554943
- Locations
- 🇧🇪
Jules Bordet Institute, Brussels, Belgium
Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer
- First Posted Date
- 2012-02-23
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 18
- Registration Number
- NCT01537536
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01513109
- Locations
- 🇧🇪
Institut Jules Bordet, tumor center of the Universite Libre de Bruxelles, Brussels, Belgium
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 90
- Registration Number
- NCT01481701
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01420146
- Locations
- 🇧🇪
Jules Bordet Institut, Brussels, Belgium
Early Cardiac Toxicity of Adjuvant CT in Elderly BC.
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 2
- Registration Number
- NCT01301040
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 97
- Registration Number
- NCT01290926
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪Hopitaux St Joseph, Liege, Belgium
🇧🇪Universiteit Ziekenhuis Antwerpen, Antwerpen, Belgium
Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 235
- Registration Number
- NCT00994864
- Locations
- 🇧🇪
Clin Université St-Luc Bruxelles, Brussels, Belgium
🇧🇪Hôpital Erasme, Brussels, Belgium
🇧🇪CHU De Liège, Liège, Belgium
PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome.
- Conditions
- Interventions
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00741481
- Locations
- 🇧🇪
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium